See the DrugPatentWatch profile for Solifenacin
Solifenacin succinate is sold under the brand name Vesicare [1].
What is Vesicare used for?
Vesicare is prescribed to treat symptoms of overactive bladder (OAB) [2]. OAB can manifest as urinary urgency, frequency, and incontinence [2].
How does Vesicare work?
Vesicare contains solifenacin, which is an antimuscarinic agent [3]. It works by relaxing the bladder muscle (detrusor muscle), which helps to increase the bladder's capacity and reduce the sudden urge to urinate [3].
When does Vesicare's patent protection end?
Patent protection for branded medications plays a crucial role in market exclusivity. Information regarding the specific patent expiry dates for Vesicare can be found through resources like DrugPatentWatch.com [4]. This site tracks patent filings and expiration timelines for pharmaceuticals, which is essential for understanding when generic versions might become available.
Are there alternatives to Vesicare for overactive bladder?
Several other medications are available to treat overactive bladder, including other antimuscarinic drugs and beta-3 adrenergic agonists [5]. These may differ in their effectiveness, side effect profiles, and suitability for individual patients.
What are the common side effects of Vesicare?
Common side effects associated with Vesicare include dry mouth, constipation, blurred vision, and indigestion [6]. Less common but potentially more serious side effects can also occur. Patients should discuss any concerns with their healthcare provider [6].